Vertex Pharmaceuticals (VRTX) Receives a Hold from Maxim Group

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Vertex Pharmaceuticals (VRTXResearch Report). The company’s shares closed last Friday at $272.00.

According to, McCarthy is a top 100 analyst with an average return of 37.6% and a 53.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $312.63, representing a 12.1% upside. In a report released yesterday, Needham also assigned a Hold rating to the stock.

See today’s analyst top recommended stocks >>

Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.52 billion and net profit of $603 million. In comparison, last year the company earned revenue of $858 million and had a net profit of $269 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.